(Q42919961)

11 November 2017

title

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. (English)

1 reference

single-nucleotide polymorphism

11 November 2017

main subject

1 reference

1 reference

1

1 reference

11 November 2017

5

T P Hughes

1 reference

11 November 2017

V A Saunders

2

1 reference

11 November 2017

P Dang

series ordinal

3

1 reference

11 November 2017

J Engler

series ordinal

4

1 reference

11 November 2017

publication date

2 September 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

24

1 reference

11 November 2017

issue

11

1 reference

11 November 2017

page(s)

1962-1965

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2010.188

11 November 2017

exact match

0 references

cites work

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.188

21 January 2018

Identifiers

DOI

10.1038/LEU.2010.188

1 reference

Dimensions Publication ID

11 November 2017

1031735878

0 references

1 reference